Transcend Capital Advisors’s Ginkgo Bioworks DNA Stock Holding History

Transcend Capital Advisors’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,089	Closed	-$73.6K	–	492
2022 Q4	$73.6K	Hold	1,089	–	–	0.01%	479
2022 Q3	$136K	Hold	1,089	–	–	0.02%	458
2022 Q2	$104K	Hold	1,089	–	–	0.01%	480
2022 Q1	$176K	Buy	+1,089	New	+$212K	0.02%	488

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Transcend Capital Advisors's DNA Position: Q1 2023 in Review

Transcend Capital Advisors sold out of Ginkgo Bioworks (DNA) in Q1 2023, closing a stake of 1,089 shares — an estimated $73.6K sold.

Transcend Capital Advisors first reported a position in DNA in Q1 2022 and held it in 4 quarters. The position peaked at $176K in Q1 2022. 313 funds tracked by Wall St. Rank hold DNA as of Q1 2023.

Transcend Capital Advisors reported no remaining Ginkgo Bioworks position as of Q1 2023 after selling out during the quarter.
Transcend Capital Advisors sold 1,089 Ginkgo Bioworks shares in Q1 2023, an estimated $73.6K.
Transcend Capital Advisors first reported a position in Ginkgo Bioworks in Q1 2022 and held it in 4 quarters.
Transcend Capital Advisors's Ginkgo Bioworks position peaked at $176K in Q1 2022.
313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2023.

Based on Transcend Capital Advisors's 13F filing for Q1 2023, filed 12 Apr 2023.